全文获取类型
收费全文 | 1059篇 |
免费 | 72篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 59篇 |
妇产科学 | 11篇 |
基础医学 | 89篇 |
口腔科学 | 29篇 |
临床医学 | 183篇 |
内科学 | 282篇 |
皮肤病学 | 12篇 |
神经病学 | 26篇 |
特种医学 | 244篇 |
外科学 | 66篇 |
综合类 | 26篇 |
预防医学 | 32篇 |
眼科学 | 8篇 |
药学 | 35篇 |
中国医学 | 5篇 |
肿瘤学 | 28篇 |
出版年
2023年 | 8篇 |
2022年 | 3篇 |
2021年 | 13篇 |
2020年 | 6篇 |
2019年 | 6篇 |
2018年 | 27篇 |
2017年 | 13篇 |
2016年 | 20篇 |
2015年 | 21篇 |
2014年 | 32篇 |
2013年 | 27篇 |
2012年 | 21篇 |
2011年 | 26篇 |
2010年 | 43篇 |
2009年 | 56篇 |
2008年 | 31篇 |
2007年 | 10篇 |
2006年 | 21篇 |
2005年 | 8篇 |
2004年 | 11篇 |
2003年 | 18篇 |
2002年 | 15篇 |
2001年 | 16篇 |
2000年 | 11篇 |
1999年 | 12篇 |
1998年 | 50篇 |
1997年 | 52篇 |
1996年 | 64篇 |
1995年 | 49篇 |
1994年 | 43篇 |
1993年 | 47篇 |
1992年 | 19篇 |
1991年 | 8篇 |
1990年 | 22篇 |
1989年 | 35篇 |
1988年 | 32篇 |
1987年 | 36篇 |
1986年 | 34篇 |
1985年 | 29篇 |
1984年 | 19篇 |
1983年 | 13篇 |
1982年 | 24篇 |
1981年 | 15篇 |
1980年 | 10篇 |
1979年 | 7篇 |
1978年 | 7篇 |
1977年 | 16篇 |
1976年 | 13篇 |
1975年 | 13篇 |
1969年 | 2篇 |
排序方式: 共有1138条查询结果,搜索用时 282 毫秒
41.
Jennifer VanderWeele Teresa Pollack Diana Johnson Oakes Colleen Smyrniotis Vidhya Illuri Priyathama Vellanki Kevin OLeary Jane Holl Grazia Aleppo Mark E. Molitch Amisha Wallia 《Journal of diabetes and its complications》2018,32(7):650-654
Aims
This study validated enterprise data warehouse (EDW) data for a cohort of hospitalized patients with a primary diagnosis of diabetic ketoacidosis (DKA).Methods
247 patients with 319 admissions for DKA (ICD-9 code 250.12, 250.13, or 250.xx with biochemical criteria for DKA) were admitted to Northwestern Memorial Hospital from 1/1/2010 to 9/1/2013. Validation was performed by electronic medical record (EMR) review of 10% of admissions (N?=?32). Classification of diabetes type (Type 1 vs. Type 2) and DKA clinical status were compared between the EMR review and EDW data.Results
Key findings included incorrect classification of diabetes type in 5 of 32 (16%) admissions and indeterminable classification in 5 admissions. DKA was not present, based on the review, in 11 of 32 (34%) admissions. DKA was not present, based on biochemical criteria, in 15 of 32 (47%) admissions.Conclusions
This study found that EDW data have substantial errors. Some discrepancies can be addressed by refining the EDW query code, while others, related to diabetes classification and DKA diagnosis, cannot be corrected without improving clinical coding accuracy, consistency of medical record documentation, or EMR design. These results support the need for comprehensive validation of data for complex clinical populations obtained through data repositories such as the EDW. 相似文献42.
Human platelet membrane glycoproteins IIb and IIIa (GPIIb and IIIa) were incorporated into phospholipid vesicles by the reverse-phase technique to assess the ability of GPIIb and IIIa to function as a Ca2+ channel. Movement of Ca2+ across the lipid bilayer was quantitated by injection of proteoliposomes with encapsulated Fura-2 into Ca2+ buffers and measurement of Fura-2 fluorescence as an indicator of Ca2+ influx. Reciprocally, to assess the function of proteins in an inside-out orientation, Ca2+-loaded vesicles were injected into Ca2+-free buffer and Ca2+ efflux monitored by a calcium electrode. Incorporation of the IIb-IIIa complex produced significant facilitation of Ca2+ movement across the lipid bilayer. No net transmembrane Ca2+ movement was seen with dissociated IIb and IIIa. Movement of Ca2+ was proportional to the transmembrane Ca2+ gradient. Ca2+ movement into the vesicles was inversely proportional to extravesicular NaCl from 25 to 150 mmol/L, analogous to several studies in the intact platelet. Adenosine triphosphate had no effect on Ca2+ movement into or out of the vesicles. Specific inhibition of a Ca2+ shift into the vesicles was seen with M148, a monoclonal antibody to IIb/IIIa, while no inhibition was observed with a panel of other anti-IIb/IIIa monoclonal antibodies. This suggests that a specific site on the complex or orientation of the complex is essential for calcium channel function. These data demonstrate that the GPIIb/IIIa complex can serve as a passive Ca2+ channel across a phospholipid bilayer and has the potential to play a role in Ca2+ flux across the platelet plasma membrane. 相似文献
43.
Hasegawa DK; Bennett AJ; Coccia PF; Ramsay NK; Nesbit ME; Krivit W; Edson JR 《Blood》1980,56(4):585-595
Factor V deficiency has been identified in 8 of 8 patients 7--20 yr of age, with Philadelphia-positive (Ph1+) chronic myelogenous leukemia (CML). In these 8 patients, factor V deficiency was not due to hepatic dysfunction, factor V inhibitors, or disseminated intravascular coagulation. In 3 patients, factor V activity rose 10%--12% (0.10--0.12 U/ml) after the infusion of 28--31 ml/kg body weight of fresh frozen plasma (FFP). The rise persisted less than 14 hr. The mean measured postinfusion rise in factor V was 18% of the expected rise calculated from the volume of FFP infused in the patients' plasma volume. In 4 patients, a small transient rise in factor V activity occurred after splenectomy or plateletpheresis. Factor V deficiency was completely corrected after a marked reduction in bone marrow cellularity in 2 patients with Ph1+ CML treated with extensive chemotherapy, total body irradiation, and bone marrow transplantation. Factor V deficiency was retrospectively observed in 6 of 20 patients, ages 20--80 yr, with Ph1+ CML and 3 of 6 patients with other myeloproliferative disorders. The factor V deficiency appears to be associated with the large myeloid- megakaryocytic cell mass characteristic of CML and other myeloproliferative disorders. 相似文献
44.
45.
Roberto Salvatori Whitney W. Woodmansee Mark Molitch Murray B. Gordon Kathleen G. Lomax 《Pituitary》2014,17(1):13-21
Lanreotide depot (LD; commercial name Somatuline® Depot) is an injectable, extended-release formulation of the synthetic somatostatin analog (SSA) lanreotide. In recent clinical trials, LD was found to be suitable for self or partner administration, avoiding the need to travel to a medical facility. The Somatuline® Depot for Acromegaly (SODA) study is an ongoing, multicenter, observational study in the US investigating the efficacy, safety, convenience and symptom relief provided by LD in patients with acromegaly. Sub-analyses explore outcomes according to who administered the injection: patient, partner, healthcare provider (HCP) or a combination. Data reported here reflect one year of patient experience. Patients are eligible for inclusion if they have a diagnosis of acromegaly, are treated with LD and can give signed informed consent. Baseline data include patient demographics, previous acromegaly treatment and investigations, GH and IGF-I levels, LD dose and dose adjustment frequency. Symptom frequency, injection pain and treatment convenience are assessed using patient-reported questionnaires. As of 18 April 2012, 166 patients had enrolled in SODA. Most (72 %) achieved normal IGF-I levels after 12 months of LD treatment. Disease control was similar in self or partner injectors and in patients who received injections from their HCP, although self or partner injecting was deemed more convenient. LD was well-tolerated irrespective of who performed the injection. Self injection led to more injection-site reactions, but this did not increase the rate of treatment interruption. Acromegaly symptoms remained stable. Biochemical, safety and convenience data support the clinical validity of injecting LD at home. 相似文献
46.
47.
非酒精性脂肪性肝炎(non—alcoholicsteatohepatitis,NASH)现已成为肝移植愈来愈重要的基础肝病。鉴于晚期NASH患者常并存多种影响肝移植转归的临床问题,而至今尚无针对NASH患者进行肝移植的评估和治疗指南,为此英国移植学会(British Transplant Society,BTS)邀请相关专家制定了指南,以指导肝移植前后NASH患者的处理。 相似文献
48.
49.
Florian ME Wagenlehner Christoph Lichtenstern Caroline Rolfes Konstantin Mayer Florian Uhle Wolfgang Weidner Markus A Weigand 《International journal of urology》2013,20(10):963-970
Urosepsis is defined as sepsis caused by a urogenital tract infection. Urosepsis in adults comprises approximately 25% of all sepsis cases, and is in most cases due to complicated urinary tract infections. The urinary tract is the infection site of severe sepsis or septic shock in approximately 10–30% of cases. Severe sepsis and septic shock is a critical situation, with a reported mortality rate nowadays still ranging from 30% to 40%. Urosepsis is mainly a result of obstructed uropathy of the upper urinary tract, with ureterolithiasis being the most common cause. The complex pathogenesis of sepsis is initiated when pathogen or damage‐associated molecular patterns recognized by pattern recognition receptors of the host innate immune system generate pro‐inflammatory cytokines. A transition from the innate to the adaptive immune system follows until a TH2 anti‐inflammatory response takes over, leading to immunosuppression. Treatment of urosepsis comprises four major aspects: (i) early diagnosis; (ii) early goal‐directed therapy including optimal pharmacodynamic exposure to antimicrobials both in the plasma and in the urinary tract; (iii) identification and control of the complicating factor in the urinary tract; and (iv) specific sepsis therapy. Early adequate tissue oxygenation, adequate initial antibiotic therapy, and rapid identification and control of the septic focus in the urinary tract are critical steps in the successful management of a patient with urosepsis, which includes early imaging, and an optimal interdisciplinary approach encompassing emergency unit, urological and intensive‐care medicine specialists. 相似文献
50.